TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04173741

Intervention type: OTHER
Intervention: USG measurement
Description: IVC was visualized in the subxiphoid long axis by using convex probe (5-1 MHz). Diameters of IVC was measured 2 cm caudally to the junction of hepatic vein in M-mode. IJV diameter was measured in the short axis by using linear probe (12-5 MHz) and M-mode. IJV visualized in the junction of cricothyroid membrane level and midclavicular line. Maximum and minimum diameter values were measured in the M mode. Distensibility (maximum diameter - minimum diameter / minimum diameter) and collapsibility (maximum diameter - minimum diameter / maximum diameter) indices were calculated after USG measurements were done.

Intervention type: OTHER
Intervention: USG measurement
Description: IVC was visualized in the subxiphoid long axis by using convex probe (5-1 MHz). Diameters of IVC was measured 2 cm caudally to the junction of hepatic vein in M-mode. IJV diameter was measured in the short axis by using linear probe (12-5 MHz) and M-mode. IJV visualized in the junction of cricothyroid membrane level and midclavicular line. Maximum and minimum diameter values were measured in the M mode. Distensibility (maximum diameter - minimum diameter / minimum diameter) and collapsibility (maximum diameter - minimum diameter / maximum diameter) indices were calculated after USG measurements were done.
Study: NCT02504788

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hippocampal-sparing WBRT
Study: NCT04269395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAL Cream
Description: No intervention will be administered as a part of this study. Participants who received MAL cream in RD.06.SPR.112199 study will be rolled over in the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: No intervention will be administered as a part of this study. Participants who received vehicle cream in RD.06.SPR.112199 study and achieved complete response, will be rolled over in the study.
Study: NCT03512548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant 350mg
Description: Relacorilant 350mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant 350mg
Description: Relacorilant 350mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant 300mg
Description: Relacorilant 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant 300mg
Description: Relacorilant 300mg
Study: NCT02128126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISA101/ISA101b
Description: Four dose levels ISA101/ISA101b
Study: NCT01200784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide
Description: dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: dosage
Study: NCT01764633

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
Study: NCT00433329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Oral bosentan 62.5 mg BID first 4 weeks followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Oral sildenafil 20 mg TID in patients who do not reach the 6-MWT distance threshold at Week 16
Study: NCT01575210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP mask
Description: A new vent CPAP mask system will be used in this trial.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP mask
Description: A new vent CPAP mask system will be used in this trial
Study: NCT02183090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam ampoule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam tablet
Study: NCT02296242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVD-523
Description: Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
Study: NCT04113915

Intervention type: DRUG
Intervention: triple therapy
Description: Effect of treatment on immunity to obtain infection with hepatitis B\&C

Intervention type: DRUG
Intervention: Steroids
Description: Oral or parenteral steroid therapy for ITP
Study: NCT00257010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almotriptan Malate
Description: Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain
Study: NCT00883675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel-Carboplatin
Description: Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin AUC 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses
Study: NCT00984750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetyl-L-carnitine/statin (simvastatin)
Description: acetyl-L-carnitine: 4 tablets of 500 mg a day~simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo: 4 tablets of 500 mg a day simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability
Study: NCT04545905

Intervention type: DIAGNOSTIC_TEST
Intervention: ANC surveillance
Description: Clinic-based testing of all pregnant women during antenatal care visits.
Study: NCT02436460

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AbGn-168H
Description: Humanized monoclonal antibody
Study: NCT02562326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone insulin lispro
Description: Injection immediately before the start of the individualised standard meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog®
Description: Injection immediately before the start of the individualised standard meal
Study: NCT01551979

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: intermittent Theta Burst (iTBS) pattern (20 trains of 10 bursts given with 8s intervals) will be applied at 80% of active motor threshold. Each participant will receive 600 pulses per session.~Sham participants will undergo the same procedures as those in the active rTMS group.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: intermittent Theta Burst (iTBS) pattern (20 trains of 10 bursts given with 8s intervals) will be applied at 80% of active motor threshold. Each participant will receive 600 pulses per session.~Sham participants will undergo the same procedures as those in the active rTMS group.
Study: NCT04043000

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Super 13 Pro & Prebiotics
Description: Super 13 Pro \& Prebiotics was given three times a day for four weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Super 13 Pro & Prebiotics
Description: Super 13 Pro \& Prebiotics was given three times a day for four weeks.
Study: NCT04095169

Intervention type: DIAGNOSTIC_TEST
Intervention: Complement C3d test (blood sample)
Description: Evaluation of C3d levels in EDTA samples from participants

Intervention type: DIAGNOSTIC_TEST
Intervention: Complement C3d test (blood sample)
Description: Evaluation of C3d levels in EDTA samples from participants

Intervention type: DIAGNOSTIC_TEST
Intervention: Complement C3d test (blood sample)
Description: Evaluation of C3d levels in EDTA samples from participants
Study: NCT00949156

Intervention type: PROCEDURE
Intervention: Different surgical approach and techniques being used to treat three subtype of CP
Description: According to the presurgical MRI, with the analysis of the morphological characteristic of three subtype of CP, different surgical approach and intrasurgical skills were used to treat tumors with trying to total remove tumor and avoid the hypothalamus injury.
Study: NCT01497977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phytoestrogens
Description: The red clover capsule consisted of 4 isoflavones: biokain A (23mg), daidzein (1mg), formononetin (15mg) and genistein (1mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phytoestrogens
Description: The soya daily dose contained 2 isoflavones: genistein (39mg) and daidzein (1mg).
Study: NCT01826708

Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: Identification of breakpoints
Description: Identification of breakpoints in Molecular Biology : demonstration of a chimeric sequence corresponding to a junction region between the two chromosomes
Study: NCT00663741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib (400 mg bid) + S-1 (40 mg/m2 bid, 3 weeks on / 2 weeks off) + CDDP (60 mg/m2 on Day 8) / 35 days / cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib (400 mg bid) + S-1 (25 mg/m2 bid, 3weeks on / 1 week off) + CDDP (75 mg/m2 on Day 1) / 28 days / cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib (400 mg bid) + S-1 (40 mg/m2 bid, 3 weeks on / 1 week off) + CDDP (75 mg/m2 on Day 1) / 28 days cycle
Study: NCT03105830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iv paracetamol
Description: iv paracetamol
Study: NCT02738190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: Albumin 5% added to blood priming solution

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Description: Fresh Frozen Plasma added to blood priming solution
Study: NCT01194609

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune cell
Description: InnoLak two consecutive weeks every 3 weeks for 3 times

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose radiation
Description: 20cGy whole body radiation every three weeks for three times
Study: NCT02437279

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery of the tumor

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery of the tumor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infusion with ipilimumab 3 mg/kg q3wks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infusion with ipilimumab 3 mg/kg q3wks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infusion with nivolumab 1 mg/kg q3wks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infusion with nivolumab 1 mg/kg q3wks
Study: NCT00743548

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IB = Interdental brush, the intervention
Description: IB is a small multi-tufted brush on a wire attached to a long angled handle that is inserted in a horizontal plane between the teeth. The IB is inserted once and removed.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DF = Dental floss, the positive control
Description: DF is waxed dental floss; nylon covered with a water soluble unflavoured wax to facilitate easier access the contact points of teeth. DF is rubbed against the interproximal surfaces of the teeth 2-4 times on each surface.
Study: NCT02784938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocational Empowerment Photovoice (VEP)
Description: The VEP program is a 10-week manualized, structured, peer-led intervention delivered in 2-hour group sessions. The VEP manual includes a Workbook for the clients and a corresponding Leader's Guide for the group peer-leaders. The VEP program integrates Photovoice methodology, Rehabilitation Readiness technology and elements of the Anti-Stigma Photovoice (ASP) curriculum previously developed and tested by the Boston University Center for Psychiatric Rehabilitation (BU CPR). VEP group sessions combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing employment services and opportunities, all refined with input from individuals with a lived experience.
Study: NCT03792074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT510
Description: SCT510 Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin injection
Study: NCT03832257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECHO CT Intervention
Description: weekly video conference between hospitalist and skilled nursing facilities

Intervention type: OTHER
Group type: OTHER
Intervention: Matched Non-Participating Facilities
Description: Matched Non-Participating Facilities
Study: NCT00149500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Patients received monthly calls to assist in behavioral change relative to asthma care
Study: NCT02246920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: 50 mcg/actuation Nasal Spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flonase®
Description: 50 mcg/actuation Nasal Spray
Study: NCT04552678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating, Active Play, Self-Regulation, Parent Education
Description: In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
Study: NCT00372437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD0103
Description: MGCD0103 as an oral dose three times per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m\<2\> intravenously days 1, 8, 15 of a 28 day cycle.
Study: NCT02483741

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Manuka Honey
Description: This material is going to be placed into the sockets of the extracted third molars in the experimental group
Study: NCT02021409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Study: NCT00094757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: sitagliptin 100 mg
Description: sitagliptin 100 mg oral tablet once daily for 54 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: sitagliptin 200 mg
Description: sitagliptin 200 mg (2- 100 mg oral tablets) once daily for 54 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: placebo oral tablet once daily during Phase A (Weeks 0-18)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: pioglitazone
Description: pioglitazone 30 mg oral tablet once daily during Phase B (Weeks 18-54)
Study: NCT03440359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone Vaginal Gel 8%
Description: progesterone supplementation for luteal phase support administered with vaginal applicators and used instead of progesterone intramuscular injections or progesterone vaginal suppositories.

Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole Oral Tablet
Description: letrozole oral tablet 2.5 mg or 5 mg administered cycle day 3-7 for ovulation induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole Oral Tablet
Description: letrozole oral tablet 2.5 mg or 5 mg administered cycle day 3-7 for ovulation induction

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: pelvic ultrasound
Description: pelvic ultrasound performed at cycle day 11 or 12 and repeated as necessary until leading follicle size is \>17 mm in diameter

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: pelvic ultrasound
Description: pelvic ultrasound performed at cycle day 11 or 12 and repeated as necessary until leading follicle size is \>17 mm in diameter

Intervention type: DRUG
Group type: OTHER
Intervention: Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe
Description: ovidrel 250 mcg given when leading follicle size is \> 17 mm in diameter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe
Description: ovidrel 250 mcg given when leading follicle size is \> 17 mm in diameter

Intervention type: OTHER
Group type: OTHER
Intervention: Intrauterine insemination or timed intercourse
Description: Intrauterine insemination or timed intercourse (depending on semen parameters) performed 36-40 hours after Ovidrel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine insemination or timed intercourse
Description: Intrauterine insemination or timed intercourse (depending on semen parameters) performed 36-40 hours after Ovidrel
Study: NCT00518479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 160mg OD; Moxonidine 400mcg OD
Study: NCT03739528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin + dexamethasone followed by dexamethasone
Description: Levofloxacin + dexamethasone ophthalmic solution for 7 days, 1 drop - 4 times a day, followed by dexamethasone ophthalmic suspension (Maxidex®) for an additional 7 days, 1 drop - 4 times a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin + Dexamethasone
Description: Tobramycin + dexamethasone ophthalmic suspension (Tobradex®) for 14 days, 1 drop - 4 times a day.
Study: NCT02710409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine
Description: 0.5 ml/vial, one dose, intramuscular injection on day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine A
Description: 0.5 ml/vial, one dose, intramuscular injection on day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine B
Description: 0.5 ml/vial, one dose, intramuscular injection on day 0
Study: NCT00087373

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-TRICOM vaccine
Description: Given intratumorally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01906125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palbociclib capsule: phase 1 and 2 studies
Description: 125 mg dose of palbociclib. Formulation used in phase 1 and 2 studies
Study: NCT02246920

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive Nasal Spray
Study: NCT04217551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.
Study: NCT01906125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib capsule: phase 3 studies
Description: 125 mg dose of palbociclib. Formulation used in phase 3 studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib capsule: ICH
Description: 125 mg dose of palbociclib. Intended final market formulation